Background: Dysregulation of mTOR signaling by mutations in tuberin and/or hamartin leads to the formation of tuberous sclerosis complex (TSC). Trials to treat TSC using mTOR inhibitors, including rapamycin, have been performed. Although rapamycin improves many TSC lesions, significant side effects appear after systemic administration. Topical administration has been recommended.
Objectives: The efficacy of rapamycin-tacrolimus ointment was examined for TSC-related angiofibroma.
Methods: Left-right comparisons of the tacrolimus ointments with/without 0.2% rapamycin was conducted in symmetrical facial angiofibromas in 9 definitive TSC patients. After the 3-month treatment, a cumulative score for redness, flatness, ...
A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex : A pilot study of 9 Japanese TSC patients with different disease severity is a post from: Skincare
A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex : A pilot study of 9 Japanese TSC patients with different disease severity via BuzzBlazer.com
No comments:
Post a Comment